U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07551050) titled 'Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer' on April 20.
Brief Summary: A real-world, multicenter, prospective study to evaluate the patient-reported outcome in Chinese patients who received sacituzumab govitecan or chemotherapy of the physician's choice for metastatic breast cancer progressing on first-line treatment
Study Start Date: May 15
Study Type: OBSERVATIONAL
Condition:
TNBC - Triple-Negative Breast Cancer
Recruitment Status: RECRUITING
Sponsor: Fudan University
Information provided by (Responsible Party): Biyun Wang, MD, Fudan University
Published by HT Digital...